Triangle Securities Wealth Management Acquires 1,120 Shares of Eli Lilly and Company (NYSE:LLY)

Triangle Securities Wealth Management lifted its position in Eli Lilly and Company (NYSE:LLY) by 30.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,814 shares of the company’s stock after purchasing an additional 1,120 shares during the quarter. Eli Lilly and Company accounts for 1.0% of Triangle Securities Wealth Management’s portfolio, making the stock its 26th largest position. Triangle Securities Wealth Management’s holdings in Eli Lilly and Company were worth $3,976,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Heritage Family Offices LLP raised its stake in shares of Eli Lilly and Company by 8.9% in the first quarter. Heritage Family Offices LLP now owns 2,138 shares of the company’s stock valued at $1,765,000 after purchasing an additional 174 shares in the last quarter. Level Financial Advisors raised its stake in shares of Eli Lilly and Company by 8.7% in the first quarter. Level Financial Advisors now owns 460 shares of the company’s stock valued at $380,000 after purchasing an additional 37 shares in the last quarter. First Financial Corp IN raised its stake in shares of Eli Lilly and Company by 0.9% in the first quarter. First Financial Corp IN now owns 4,545 shares of the company’s stock valued at $3,754,000 after purchasing an additional 41 shares in the last quarter. Romano Brothers AND Company raised its stake in shares of Eli Lilly and Company by 9.6% in the first quarter. Romano Brothers AND Company now owns 6,050 shares of the company’s stock valued at $4,997,000 after purchasing an additional 531 shares in the last quarter. Finally, Bremer Bank National Association raised its stake in shares of Eli Lilly and Company by 4.3% in the first quarter. Bremer Bank National Association now owns 13,339 shares of the company’s stock valued at $11,017,000 after purchasing an additional 554 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. This trade represents a 14.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.13% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Hsbc Global Res lowered Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday, April 28th. The Goldman Sachs Group upgraded Eli Lilly and Company from a “neutral” rating to a “buy” rating and dropped their price objective for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Morgan Stanley reiterated an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Wells Fargo & Company reiterated an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Finally, Wall Street Zen upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, May 30th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $1,011.37.

Eli Lilly and Company Price Performance

Shares of LLY opened at $750.94 on Wednesday. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The stock has a market cap of $711.69 billion, a P/E ratio of 64.13, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The stock’s 50-day moving average price is $773.82 and its two-hundred day moving average price is $799.64.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter last year, the business posted $2.58 EPS. Eli Lilly and Company’s quarterly revenue was up 45.2% on a year-over-year basis. On average, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.80%. The ex-dividend date of this dividend is Friday, May 16th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.